Dysfunction of p53-dependent pathways can allow tumour cells to evade the checkpoint controls and apoptosis, thereby gaining a selective advantage in attempting to overcome therapy (Lowe et al, 1993a). This evidence concerns the gene TP53 and neoplasm.